IX Biopharma (SGX:42C) has issued and allotted 1.7 million new shares under its performance share plan, increasing its total issued share count to 885 million, according to a Friday filing on the Singapore Exchange.
The shares, vested under grants announced in December and February, were not issued to directors or controlling shareholder. They rank pari passu with existing shares and are set to begin trading on Catalist on Feb. 25.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.